汉森制药
(002412)
| 流通市值：29.47亿 | | | 总市值：29.79亿 |
| 流通股本：4.98亿 | | | 总股本：5.03亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 61,896,678.44 | 109,909,913.2 | 74,792,141.37 | 51,127,203.84 |
| 应收票据及应收账款 | 331,271,261.58 | 356,776,565.62 | 350,546,382.38 | 303,024,192.76 |
| 其中：应收票据 | 36,201,367.88 | 35,782,436.58 | 37,403,627.25 | 43,843,734.47 |
| 应收账款 | 295,069,893.7 | 320,994,129.04 | 313,142,755.13 | 259,180,458.29 |
| 应收款项融资 | 37,716,485.67 | 35,711,276.42 | 41,668,052.47 | 49,498,386.66 |
| 预付款项 | 3,655,699.76 | 4,709,543.52 | 3,496,673.27 | 2,938,999.11 |
| 其他应收款合计 | 6,613,233.62 | 6,978,073.9 | 6,439,843.92 | 8,339,778.57 |
| 存货 | 221,548,287.8 | 221,102,091.51 | 220,524,990.88 | 231,123,272.84 |
| 其他流动资产 | 68,494,000.73 | 67,316,482.12 | 51,891,556.29 | 46,148,550.27 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,040,122,716.05 | 1,018,103,374.23 | 948,384,774.08 | 896,074,387.79 |
| 非流动资产: | | | | |
| 长期股权投资 | 838,583,389.6 | 852,908,259.3 | 851,940,451.84 | 841,806,928.81 |
| 投资性房地产 | 3,425,208.79 | 3,489,381.61 | 3,553,554.43 | 3,617,727.25 |
| 固定资产 | 472,274,965.5 | 480,129,509.35 | 488,679,469.02 | 497,867,096.66 |
| 在建工程 | 12,584,582.16 | 12,435,091.12 | 11,442,609.36 | 9,082,755.19 |
| 生产性生物资产 | 9,313,672.64 | 9,154,876.63 | 8,695,920.71 | 8,664,764.06 |
| 无形资产 | 29,491,786.16 | 29,914,475.85 | 29,215,160.26 | 29,541,613.18 |
| 商誉 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 |
| 长期待摊费用 | 14,587,890.53 | 14,767,561.55 | 14,947,232.57 | 15,126,903.59 |
| 递延所得税资产 | 2,474,912.05 | 2,552,981.3 | 2,397,913.18 | 2,495,142.33 |
| 其他非流动资产 | 15,036,555.79 | 14,985,795.79 | 16,099,277.14 | 17,421,874.74 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,412,562,393.55 | 1,435,127,362.83 | 1,441,761,018.84 | 1,440,414,236.14 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,452,685,109.6 | 2,453,230,737.06 | 2,390,145,792.92 | 2,336,488,623.93 |
| 流动负债: | | | | |
| 短期借款 | 79,795,291.53 | 90,514,320.23 | 95,120,023.83 | 95,120,023.87 |
| 应付票据及应付账款 | 23,342,888.21 | 30,027,207.74 | 29,216,994.62 | 41,105,375.58 |
| 应付账款 | 23,342,888.21 | 30,027,207.74 | 29,216,994.62 | 41,105,375.58 |
| 合同负债 | 791,335.25 | 844,550.69 | 1,072,569.05 | 6,476,951.86 |
| 应付职工薪酬 | 17,590,643.65 | 17,735,501.32 | 17,976,613.96 | 45,418,109.84 |
| 应交税费 | 6,264,413.1 | 9,336,914.02 | 11,742,079.05 | 13,927,272.52 |
| 其他应付款合计 | 182,019,217.78 | 197,020,786.87 | 182,938,103.74 | 138,085,240.38 |
| 其他流动负债 | 15,658,462.25 | 8,991,977.75 | 4,530,149.44 | 15,291,632.85 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 325,462,251.77 | 354,471,258.62 | 342,596,533.69 | 355,424,606.9 |
| 非流动负债: | | | | |
| 递延收益 | 24,967,492.96 | 20,163,688.6 | 19,070,520.6 | 16,810,272.08 |
| 递延所得税负债 | 983,186.55 | 1,004,771.46 | 1,051,265.71 | 1,224,806.28 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 25,950,679.51 | 21,168,460.06 | 20,121,786.31 | 18,035,078.36 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 351,412,931.28 | 375,639,718.68 | 362,718,320 | 373,459,685.26 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 503,200,000 | 503,200,000 | 503,200,000 | 503,200,000 |
| 资本公积 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 |
| 其他综合收益 | 17,832,929.49 | 24,410,817.17 | 16,476,595.9 | 10,342,735.82 |
| 盈余公积 | 175,822,549.32 | 175,822,549.32 | 175,822,549.32 | 175,822,549.32 |
| 未分配利润 | 1,170,300,423.24 | 1,140,041,375.62 | 1,097,812,051.43 | 1,039,547,377.26 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,101,272,178.32 | 2,077,591,018.38 | 2,027,427,472.92 | 1,963,028,938.67 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,101,272,178.32 | 2,077,591,018.38 | 2,027,427,472.92 | 1,963,028,938.67 |
| 负债和股东权益合计 | 2,452,685,109.6 | 2,453,230,737.06 | 2,390,145,792.92 | 2,336,488,623.93 |
| 公告日期 | 2024-10-29 | 2024-08-14 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |